Next, triple staining of BMNCs (CD38, CD138, and annexin V) followed by flow cytometry analysis showed that the percentages of annexin V+ non tumor cells were unchanged after 5,6 α-EC, 5,6 β-EC, or vehicle-treatment (18.8% and 18.4% vs. 17.9%) (Figure 6C). This evidence concerns the gene CD38 and neoplasm.